AZ Central: Monument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for Psychosis Monument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for Psychosis News Medical: Researchers map how brain networks differ in individuals at high clinical risk for psychosis Researchers map how brain networks differ in individuals at high clinical risk for psychosis pressconnects: Monument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for Psychosis PDP is a clinical diagnosis; no laboratory test or imaging method can definitively diagnose PDP or its symptoms. 1 Diagnostic criteria, described by the National Institute of Neurological Disorders ... The American Journal of Managed Care: Clinical Setting of Initial Psychotic Spectrum Disorder Diagnoses in an Integrated Health System This study examines the clinical settings of first-time psychotic spectrum disorder diagnoses in an integrated health system.
In this diverse cohort of patients with first-time psychotic spectrum ...
